Innovate Biopharmaceuticals Schedules Conference Call to Provide Corporate and Operational Progress Updates
26 févr. 2019 09h00 HE
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and...
Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts Focusing on the Molecular Biology and Pharmacology of Larazotide for the 2019 Digestive Disease Week Conference
25 févr. 2019 09h30 HE
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and...
Innovate Biopharmaceuticals Announces a New Chief Executive Officer and Chief Medical Officer
22 févr. 2019 10h00 HE
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for...
Innovate Biopharmaceuticals Announces Presentation at BIO CEO & Investor Conference
07 févr. 2019 08h34 HE
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT) a clinical stage biotechnology company focused on developing novel autoimmune and inflammation...
Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease in 1H 2019 and Announce Top-line NASH Data with Drug Combinations by EASL 2019
17 déc. 2018 08h00 HE
|
Innovate Biopharmaceuticals, Inc
Preliminary top-line data from the alcoholic steatohepatitis (ASH) collaboration with Massachusetts General Hospital shows positive effect of larazotide on ethanol-induced permeability in vitro ...
Innovate Biopharmaceuticals Enters into a Collaboration with Massachusetts General Hospital and Announces Capital Update for the Celiac Disease Clinical Program and its NASH Development Strategy on December 17, 2018
04 déc. 2018 11h15 HE
|
Innovate Biopharmaceuticals, Inc
-- Announces collaboration in high unmet need Alcoholic Liver Diseases (ALD), including severe alcoholic hepatitis, with novel gut-specific, clinical-stage asset, larazotide acetate-- Investor update...
Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P.
26 nov. 2018 06h00 HE
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and...
Innovate Biopharmaceuticals Reports Third Quarter 2018 Earnings and Key Corporate Highlights
13 nov. 2018 17h26 HE
|
Innovate Biopharmaceuticals, Inc
Poster presentation at the American Association of Study of Liver Diseases showing promising pre-clinical data of larazotide acetate in NASH reducing intestinal permeability. Innovate plans to...
Sanyal Biotechnology and Innovate Biopharmaceuticals Present Data at AASLD Validating a Proprietary “Leaky Gut” Assay Demonstrating Reduced Intestinal Permeability with Larazotide Acetate Treatment in a NASH Preclinical Study
12 nov. 2018 08h10 HE
|
Innovate Biopharmaceuticals, Inc
Significant effect on gut epithelial integrity, a mechanism thought to be key for bacterial translocation leading to NAFLD and NASH. Innovate plans to launch a clinical development program for NASH in...
Innovate Biopharmaceuticals Announces Presentation at the BIO-Europe Conference, Copenhagen 2018 - 24th Annual Partnering Conference
05 nov. 2018 09h15 HE
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Innovate) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for...